ArticleJournal of diabetes investigation2026
Risk of end-stage renal disease in Korean patients with type 2 diabetes according to cumulative low-density lipoprotein cholesterol levels.
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLifelong cumulative high low-density lipoprotein cholesterol (LDL-C) levels are associated with atherosclerosis burden. This study analyzed the association between cumulative LDL-C levels and the risk of end-stage renal disease (ESRD) in Korean adults with type 2 diabetes (T2D). RESEARCH DESIGN AND
methodsThe incidence of ESRD was analyzed in Korean type 2 diabetes patients aged >20 years who underwent national health examinations from 2015 to 2016. Cumulative LDL-C levels were categorized based on the number of times the levels were ≥130 mg/dL during the examinations. The risk of ESRD across groups was analyzed using the Kaplan-Meier method and Cox proportional hazards model.
resultsAmong 318,645 patients, the number of occurrences of cumulative LDL ≥130 mg/dL were 0 (154,535), 1 (63,521), 2 (42,563), 3 (32,423), and ≥4 (25,594). Using a multivariable model with adjustment for multiple confounding variables, the risk of ESRD increased with the number of high cumulative LDL-C: hazard ratio (HR) 1.33 (95% confidence interval [CI] 1.17-1.50), 1.51 (1.29-1.76), 1.99 (1.29-1.76), and 2.05 (1.66-2.54) for 1 to ≥4 occurrences, respectively. In patients taking three oral antidiabetic medications, the HR of ESRD was 1.51 (1.23-1.84), 2.10 (1.66-2.66), 3.07 (2.34-4.03), and 3.11 (2.05-2.72) for 1 to ≥4 occurrences compared with 0, respectively. For patients with diabetes duration ≥10 years, the HR of ESRD was 1.45 (1.24-1.70), 1.93 (1.59-2.35), 2.47 (1.94-3.15), and 2.97 (2.18-4.03) for 1 to ≥4 occurrences, respectively.
conclusionsESRD risk increased with high cumulative LDL-C levels. This difference was more pronounced in patients with diabetes taking multiple antidiabetic medications and in those with a longer duration of diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.